Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The stock is being manipulated down and trades like that show it.
It's possibl but Roth made a commitment they wouldn't sell. It could be the investors Roth brought in.
I don't think anyone who invested in any of the PIPE's are selling or have sold anything. They're in this for the long haul. This is price manipulation on a company with a very low profile.
They're going to be able to fast track their chemo side effect drug which would take about 18 months to 2 years.
I've been to their headquarters. They're legit. They have 4 people working on the day to day operations including numerous trips to the university. If anyone is worried this is a scam, look at who's involved in this and the fact that there has been no inside selling and won't be until this hits.
I'm not sure the volume is warrant related. I know who they raised money from and issued stock to and they're not selling. It seems like this stock is being manipulated to stay in this range. I don't know enough as to why it would be but I've seen higher bids ignored for lower ones.
Nemus has the lowest market cap of every cannabinoid/cannabis stock publicly traded which doesn't make sense considering what they have and it's one of the few legit companies in the sector.
NMUS over IMLFF. More IP, further ahead in their glaucoma drug and have already made their chemo drug through biosynthesis. Not sure about OWC and what they really have.
You're right. Nemus has the lowest market cap of every cannabinoid/cannabis company publicly traded which is just insane.
The one knock on these guys is they have not focused on marketing the company to the cannabis investor. Alan Brochstein and others don't have Nemus listed on their daily stock updates and the ETF basically used those lists. Nemus is a cannabinoid company like GW, Zyne and a few others and not a cannabis company, but that doesn't mean they shouldn't market to the cannabis investor market. Many investors are interested in both.
Does anyone know the difference between the biosynthesis process InMed is filing patents on and the biosynthesis process Teewinot has patented and is currently licensing out to Nemus and others for their cannabinoid drug candidates? It seems like Teewinot is already ahead of the game as they can create a cannabinoid through biosynthesis in 48 hours and are already licensing it out.
Thank you
Do you know why their biosynthesis technology would be useful to companies who already make their drugs synthetically? Is it cheaper and have they tested it to FDA specifications yet?
Ideally they would get a partnership deal for funds to move it along if their IP is compelling enough. I'm interested too but they haven't made their glaucoma drug and I can't figure out if their biosynthesis is valuable. Everyone who is developing cannabinoid drugs have made them synthetically and aren't using the plant.
It's my understanding that any drug derived from the plant will be considered Schedule I by the FDA. I know Zyne, Insys, Nemus and others synthetically make their drugs and never touch the plant. Is GW really still making their drug from the plant?
Do you know if InMed has shown they can make either of their drugs to FDA standards? Trying to find out before I pull the trigger.
Thinking about getting in this but have a question for anyone who knows. Has InMed shown they can make either of their drugs to FDA standards? It takes a long time and is critical for going forward. Thank you.
It is a big deal as well as being able to make their lead drug to FDA standards. Nobody recognizes what they have yet. This stock should be at $2 right now.
If you look at the management team they are all very wealthy. They are all involved because they believe in this. Being the first to tap into U of M's cannabis patents is a potential goldmine. I guarantee nobody in management will sell until this has hit. They're in it because this is a once in a lifetime opportunity. How many drug companies can develop a drug knowing there won't be any safety issues that would shelve it and where they already know the drugs work because there's been more research done than any other drug?
They have done nothing to promote Nemus other than press releases because they know where this is going. It's comes down to getting a development partner and/or fast tracking their lead candidate. Take a look at what they have and who's involved if you want to gauge if they'll be able to execute.
Yep. Totally manipulated down. Anyone who holds has to be patient. I think they're going to be able to execute and this will shoot to the $3 range on big news which I expect in the next 3 months.
The MM 's are manipulating the price. I've messed around and bid .05 higher than any other bid and couldn't get my order filled.
I think you can expect to stay in this range. The large holders of this stock know what they have and are holding until this hits. Everyone is waiting for the big news about a deal or a fast track filing. Although I think if Nemus marketed this better and people really understood what they have, this would be trading in the $2 range.
This is a stock that you can't worry about charts and pricd fluctuations. This is the least marketed company in the space. There are long periods with no news and the stock sits with low volume. Then news comes out and there's a week or two of high volume and the price goes up then it goes back down until more news. The bet here is they get a partnership to move their candidates along and that they'll be able to fast track one of their drugs. They'll either execute or not but there is no risk their drugs won't work. That's a pretty big part of the equation in a biotech stock. This is a very good management team that has done a good job with dilution compared to others and won't dump. They have a tough road but they know what they're doing. Good luck.
Thank you for the info. Insiders will never sell until this hits and the underwriter made a commitment not to sell and hasn't. My guess is that there was demand after the recent article and market makers manipulate the price when volume is down.
As far as clinical trials go, I don't think they're going to be in clinicals on the glaucoma drug until 2nd quarter but I think they will apply for fast track on the chemo side effects candidate soon and my not need clinicals. That announcement will make this stock explode.
1 share dilution is bad? Wow. It really doesn't matter. If you're in this short term and worried about what the price does over the next few months then you should get out.
There has been no insider dumping and they have made huge scientific strides including pored that they can make one of their drugs. It took GW 12 years to make theirs and Zynerba 6 years.
They're either going to get a partnership deal done this year and fast track their leading candidate or they're not. It's all about execution. Calling it garbage means you shouldn't be in the stock and have no idea what this group is doing.
Besides GW and Zynerba, name a better publicly traded cannabanoid company in terms of IP and dilution.
How much is a ton? The investors they've had have been long term holders so far.
I can tell you with 100% confidence that management hasn't sold any shares and neither has Roth.
They're not hiding anything really. They've disclosed what they have for the most part but haven't done a great job marketing it, One thing I think they do have up their sleeve is a 505 b 2 filing on their chemo side effect drug. This will pop on that news.
Fast tracking their neuropathy drug is a definite possibility as it's similar to Marinol and the other approved drugs. If that happens, it takes about 1.5 years to get approval.
I would look into if they can make the drug or if they're in the process of proving they can make it. It will take a year to do and more likely 2 years. If they don't have that, they're a long way from getting human data and way behind in the race. And that's assuming their IP is on par with Nemus'.
One thing to watch out for is being able to synthetically make the drug to FDA purification standards. Nemus has shown they can do it and that is a big deal. It's not an easy task as it took other companies a lot longer than it took Nemus. I don't know if Inmed has done it yet but if they haven't, Nemus is way ahead of them.
I also believe Nemus has superior IP and mangement. Murphy is the real deal who has a track record of developing other drugs.
I think they're several months off on human trials. I think the nausea drug will be the first to bring in money because it's a known quantity and likely to get fast track approval. I would expect some type of partnership in the next few months to get it there. They have the drug in synthetic form that passes purification standards and they know it will pass safety standards. That's not an unknown like most drugs seeking approval. They are moving at light speed compared to what other cannabis related drug companies have. It's just a matter of time before they get backing. The stock is way undervalued.
Seeking Alpha article came out this morning of an interview with the CEO. Pretty informative on what they have. If you read between the lines he is politely saying Nemus has the potential to be much more valuable than GW and Zynerba. That they have what other companies in the sector will need.
Nemus just needs to do a better job in marketing what they have.
The only shares that might hit the market are the ones Roth acquired. No insiders have or will sell until this is successful. Nemus has the lowest market cap of any cannabis stock so it's clearly undervalued. Management needs to do a better job of marketing the company.
There are only 2 salaries plus rent. These guys are already wealthy. They're only going to make money if this thing hits. All of them could work anywhere so they believe in what they're doing. Personally, I'd like them to have a higher profile and pump this thing some but they're just grinders pushing this further along.
thank you for the info. I'm curious, why do you think it's only trading at .17 if they're so far along?
My understanding is the patents Nemus has the rights to are very valuable with one of them related to molecular structure that will be sought after. It is also my understanding that GW does not have patent protection so their drug candidate can only be used for what it's approved for.
It should change. OWCP has a market cap 3x Nemus' and they don't have $2 million in cash or equivalent IP and their targeted indications are much more risky and costly.
I believe that's true and that they've been preparing for the past month. Where'd you see that?
Market cap. I believe Nemus has the lowest market cap of any cannabis related company being traded. That includes similar companies like IMLFF and VBIO with inferior IP and no capital and all the scam companies like CBDS, CBIS and NCAP. Unreal.
How in the world is this thing trading at $5? No revenue, no money, no IP of value and insider dumping. How's it not sub-penny?
Easy word to throw out hiding behind a keyboard. A successful, wealthy management group is running a scam in collaboration with The University of Mississippi. Is that your take?
You should go to the CBDS board if you want to pound on a real scam. That stock is at $5 with no money, no revenue or product. You could post 'scam' everyday. Good luck.
Hopefully you've sold already and don't have to worry about the price. I guess Roth Capital found some suckers to put in $1.5 million even thought it's going to zero.
The other way to look at it is they are now capitalized for another 7 months to get through their January FDA meeting and to develop their IP so they'll be able to raise more money at a better price down the road.
This could go to zero if they don't execute but clearly they have better IP than any other cannabis pharmaceutical companies.